Acquiring HemaCare expands Charles River’s scientific capabilities in the emerging, high-growth cell therapy sector, creating a comprehensive portfolio of early-stage research and manufacturing support solutions to help cell therapy developers and manufacturers advance their critical programs from basic research and proof-of-concept to regulatory approval and commercialization.
James C. Foster, Chairman, President and Chief Executive Officer of Charles River Laboratories, commented, “We are pleased to welcome the talented team at HemaCare to the Charles River family. The addition of HemaCare’s cellular products enhances our ability to provide a comprehensive cell therapy solution from discovery through commercialization, which will enhance our clients’ efficiency and accelerate their speed-to-market. The acquisition of HemaCare is a key element of our strategy to fully support our clients’ early-stage drug research efforts, achieve our long-term growth goals, and enhance shareholder value.”
Read the full press release here.
